Alternative Data for Cardiff Oncology
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | N/A | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 6,000 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 1 | Sign up | Sign up | Sign up |
| Facebook Followers | 1,229 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 124 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 18,814 | Sign up | Sign up | Sign up |
| X Followers | 1,098 | Sign up | Sign up | Sign up |
| X Mentions | 15 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 54 | Sign up | Sign up | Sign up |
About Cardiff Oncology
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California.
| Price | $1.60 |
| Target Price | Sign up |
| Volume | 925,910 |
| Market Cap | $108M |
| Year Range | $1.48 - $4.45 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Cardiff Oncology, Inc. (CRDF) Discusses Management Transition and Onvansertib Phase II Data Update in RAS-Mutated mCRC TranscriptJanuary 27 - SeekingAlpha |
 |
Cardiff Oncology: What Storms Can We Expect In 2026? The Case For Measured EnthusiasmJanuary 12 - SeekingAlpha |
 |
Cardiff Oncology initiated with bullish view at Noble Capital, here's whyJanuary 5 - Thefly.com |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 120,000 | 0 | 120,000 | -11M | -11M | -0.170 |
| Q2 '25 | 120,000 | 12M | -11M | -14M | -15M | -0.210 |
| Q1 '25 | 110,000 | 0 | 110,000 | -13M | -14M | -0.200 |
| Q4 '24 | 150,000 | 96,000 | 150,000 | -12M | -12M | -0.210 |
| Q3 '24 | 170,000 | 100,000 | 170,000 | -12M | -13M | -0.250 |
Insider Transactions View All
| PACE GARY W filed to buy 1,345,676 shares at $2.5. July 31 '25 |
| PACE GARY W filed to buy 1,330,676 shares at $2.5. July 31 '25 |
| Levine James E. filed to buy 67,716 shares at $5. December 18 '24 |
| Levine James E. filed to buy 65,316 shares at $5.4. December 18 '24 |
| Levine James E. filed to buy 62,564 shares at $3.8. December 18 '24 |
Similar companies
Read more about Cardiff Oncology (CRDF) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews & linkedin employees.
FAQ - Cardiff Oncology
The Market Cap of Cardiff Oncology is $108M.
Currently, the price of one share of Cardiff Oncology stock is $1.60.
The CRDF stock price chart above provides a comprehensive visual representation of Cardiff Oncology's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Cardiff Oncology shares. Our platform offers an up-to-date CRDF stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Cardiff Oncology (CRDF) does not offer dividends to its shareholders. Investors interested in Cardiff Oncology should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Cardiff Oncology are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
